$KRTL Holding Group, Inc. Reports Strong Year-Over-Year Growth for Second Quarter 2025
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=489405
Golden, CO – August [xx], 2025 – KRTL Holding Group, Inc. (OTC: KRTL), through its subsidiaries KRTL Biotech Inc. and KRTL International Inc., today announced financial results for the second quarter ended June 30, 2025, highlighted by substantial revenue growth and a significant increase in net income compared to the same period last year.
Second Quarter 2025 Highlights (vs. Q2 2024)
Revenue increased 1,927% to $63,358, up from $3,125 in the prior-year quarter, reflecting the launch of consulting services.
Net income rose 137% to $148,618, compared to $62,790 in the second quarter of 2024.
Unrealized gain on equity securities grew 1,267% to $1,084,940, up from $79,344 in Q2 2024.
Advanced the delivery of bulk Thiamine Mononitrate (Vitamin B1) and Riboflavin (Vitamin B2) under existing purchase orders.
Operational Update
KRTL Biotech Inc., an FDA-registered pharmaceutical company, continued to expand its biotechnology research and development activities, partnering with cGMP-compliant manufacturers, ISO-certified laboratories, and academic institutions to advance product innovation and regulatory readiness.
KRTL International Inc. strengthened its role as the Company’s distribution and consulting arm, expanding sourcing and delivery of bio- and agri-technology products, including active pharmaceutical ingredients (APIs) and specialty vitamins, while supporting clients with strategic market analysis and cross-border commercialization services.
CEO Commentary
"In the second quarter, KRTL focused on expanding its active pharmaceutical ingredient (API) portfolio, strengthening manufacturing partnerships, and advancing regulatory processes to support the potential launch of additional pharmaceutical products. At the holding company level, we continued our work to maintain compliance with applicable reporting requirements, including activities related to SEC Rule 15c2-11, which supports the availability of current and accurate company information for investors. These initiatives are intended to enhance our operational readiness and create flexibility to respond to market opportunities as they arise. While the timing and outcome of these opportunities will depend on various market and regulatory factors, we believe the steps taken this quarter have positioned our pharmaceutical divisions to operate more efficiently and in alignment with applicable compliance standards."
First Half 2025 Performance (vs. First Half 2024)
Revenue rose 252% to $96,275, up from $27,369 in the prior-year period.
Unrealized gain on equity securities totaled $545,567, up 189% from $188,713 in the first half of 2024.
Net income (loss) was a loss of $322,872, compared to net income of $94,094 in the first half of 2024, reflecting a higher price per share of our stock that resulted in higher stock-based compensation expense.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=489405
Golden, CO – August [xx], 2025 – KRTL Holding Group, Inc. (OTC: KRTL), through its subsidiaries KRTL Biotech Inc. and KRTL International Inc., today announced financial results for the second quarter ended June 30, 2025, highlighted by substantial revenue growth and a significant increase in net income compared to the same period last year.
Second Quarter 2025 Highlights (vs. Q2 2024)
Revenue increased 1,927% to $63,358, up from $3,125 in the prior-year quarter, reflecting the launch of consulting services.
Net income rose 137% to $148,618, compared to $62,790 in the second quarter of 2024.
Unrealized gain on equity securities grew 1,267% to $1,084,940, up from $79,344 in Q2 2024.
Advanced the delivery of bulk Thiamine Mononitrate (Vitamin B1) and Riboflavin (Vitamin B2) under existing purchase orders.
Operational Update
KRTL Biotech Inc., an FDA-registered pharmaceutical company, continued to expand its biotechnology research and development activities, partnering with cGMP-compliant manufacturers, ISO-certified laboratories, and academic institutions to advance product innovation and regulatory readiness.
KRTL International Inc. strengthened its role as the Company’s distribution and consulting arm, expanding sourcing and delivery of bio- and agri-technology products, including active pharmaceutical ingredients (APIs) and specialty vitamins, while supporting clients with strategic market analysis and cross-border commercialization services.
CEO Commentary
"In the second quarter, KRTL focused on expanding its active pharmaceutical ingredient (API) portfolio, strengthening manufacturing partnerships, and advancing regulatory processes to support the potential launch of additional pharmaceutical products. At the holding company level, we continued our work to maintain compliance with applicable reporting requirements, including activities related to SEC Rule 15c2-11, which supports the availability of current and accurate company information for investors. These initiatives are intended to enhance our operational readiness and create flexibility to respond to market opportunities as they arise. While the timing and outcome of these opportunities will depend on various market and regulatory factors, we believe the steps taken this quarter have positioned our pharmaceutical divisions to operate more efficiently and in alignment with applicable compliance standards."
First Half 2025 Performance (vs. First Half 2024)
Revenue rose 252% to $96,275, up from $27,369 in the prior-year period.
Unrealized gain on equity securities totaled $545,567, up 189% from $188,713 in the first half of 2024.
Net income (loss) was a loss of $322,872, compared to net income of $94,094 in the first half of 2024, reflecting a higher price per share of our stock that resulted in higher stock-based compensation expense.
